Cabaletta Bio reported no CRS or ICANS of any grade observed during the 28-day DLT observation window for either of the first patients dosed with CABA-201 in the RESET-Myositis™ and RESET-SLE™ trials. We are looking forward to presenting initial clinical data on those patients at a satellite symposium at the EULAR 2024 Congress in June. Read our Q1 2024 earnings press release here: https://lnkd.in/eTSPtw29 #CART #celltherapy #myositis #SLE #autoimmune
🤞
😎
Let’s go!! Congrats team Cabaletta Bio!!
Congratulations!
Executive Director of Quality Assurance | FDA, EMEA, CAPA, GLP, GMP, GCP, QMS, ICH, Vendor Management & Validation Expert
2moCongrats